Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

MOTIV BTK Randomized Controlled Trial

NCT05406622 · View on ClinicalTrials.gov ↗

Study Summary

Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.

Conditions Studied

Interventions

  • DEVICE MOTIV Sirolimus-Eluting Bioresorbable Scaffold
  • DEVICE Percutaneous Transluminal Angioplasty (PTA) Device

Study Locations (4)

Iowa

  • UnityPoint Health Trinity Bettendorf Hospital — Bettendorf
  • Cardiovascular Medicine PC — Davenport

California

  • Adventist Health — St. Helena

Other

  • University Leipzig — Leipzig

Trial Details

FieldValue
Enrollment Target 292 participants
Start Date 2022-06-10
Est. Completion 2029-03-31
Phase NA

Sponsor

REVA Medical

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05406622

The ClinicalTrials.gov registry entry for NCT05406622 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is REVA Medical, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Critical Limb Ischemia appearing as the primary indexed condition, and to 2 interventions — of which MOTIV Sirolimus-Eluting Bioresorbable Scaffold is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05406622 reports 4 study locations spanning 3 distinct geographic areas — top geographies include Iowa, California, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05406622 about?

NCT05406622 is a clinical study titled "MOTIV BTK Randomized Controlled Trial". Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.

What is the current status of trial NCT05406622?

This trial is currently recruiting. It is a NA study. The enrollment target is 292 participants. The study started on 2022-06-10. Estimated completion is 2029-03-31.

What conditions does trial NCT05406622 study?

This clinical trial studies the following conditions: Critical Limb Ischemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05406622?

The interventions under investigation include: MOTIV Sirolimus-Eluting Bioresorbable Scaffold (DEVICE), Percutaneous Transluminal Angioplasty (PTA) Device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05406622?

This trial is sponsored by REVA Medical, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05406622 being conducted?

This trial has 4 study locations across California, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial